Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Other Accumulated Expenses (2016 - 2026)

Iradimed has reported Other Accumulated Expenses over the past 14 years, most recently at $427000.0 for Q1 2026.

  • Quarterly Other Accumulated Expenses rose 66.16% to $427000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $427000.0 through Mar 2026, up 66.16% year-over-year, with the annual reading at $313000.0 for FY2025, 32.83% down from the prior year.
  • Other Accumulated Expenses was $427000.0 for Q1 2026 at Iradimed, up from $313000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $466000.0 in Q4 2024 and troughed at $103241.0 in Q4 2023.
  • The 5-year median for Other Accumulated Expenses is $217496.0 (2023), against an average of $230134.1.
  • The largest YoY upside for Other Accumulated Expenses was 351.37% in 2024 against a maximum downside of 45.38% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $121919.0 in 2022, then dropped by 15.32% to $103241.0 in 2023, then soared by 351.37% to $466000.0 in 2024, then plummeted by 32.83% to $313000.0 in 2025, then skyrocketed by 36.42% to $427000.0 in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Other Accumulated Expenses are $427000.0 (Q1 2026), $313000.0 (Q4 2025), and $296207.0 (Q3 2025).